Galenica Will Leverage Aspreva Acquisition To Strengthen Specialty Pharma Group
Swiss drug company seeks to buy Aspreva for roughly $915 million to accelerate development of its pharma arm.
Swiss drug company seeks to buy Aspreva for roughly $915 million to accelerate development of its pharma arm.